Case Series of Nivolumab Treatment in Patients With Relapsed/Refractory Hiv-Related Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.183_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Oncogematologiya
OncologyHematology
2018English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2014English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of an Oncolytic Viral Strategy Using Bortezomib With ICE/R in Relapsed/Refractory HIV-positive Lymphomas

Blood advances
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy